このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Exagen マネジメント
マネジメント 基準チェック /34
現在、CEO に関する十分な情報がありません。
主要情報
John Aballi
最高経営責任者
US$932.0k
報酬総額
| CEO給与比率 | 56.3% |
| CEO在任期間 | 2yrs |
| CEOの所有権 | 1.2% |
| 経営陣の平均在職期間 | 2yrs |
| 取締役会の平均在任期間 | 4.8yrs |
経営陣の近況
Recent updates
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified
Sep 06
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report
Aug 07Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price
Jul 13Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
May 21Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge
Mar 26Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report
Mar 22Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry
Jul 21Exagen appoints John Aballi as CEO
Oct 17Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers
Aug 10Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?
Jul 26Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?
Apr 05Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Dec 03Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?
Aug 06Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price
Apr 07Is Exagen (NASDAQ:XGN) Using Too Much Debt?
Mar 03Exagen issues preliminary testing revenue ahead of ICT chat
Jan 11Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?
Jan 05Exagen (XGN) Investor Presentation - Slideshow
Nov 20CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$17m |
| Mar 31 2024 | n/a | n/a | -US$19m |
| Dec 31 2023 | US$932k | US$525k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$35m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$1m | US$111k | -US$47m |
報酬と市場: Johnの 総報酬 ($USD 931.95K ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。
報酬と収益: Johnの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
John Aballi (39 yo)
2yrs
在職期間
US$931,950
報酬
Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022 and served as its Interim Chief Financial Officer since August 2024 until August 31, 2024. Mo...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman of the Board of Directors | 5.3yrs | US$132.81k | 0% $ 0 | |
| CEO, President & Director | 2yrs | US$931.95k | 1.17% $ 602.9k | |
| Corporate Secretary | 7.1yrs | US$915.09k | 0.30% $ 155.8k | |
| Investors Relations Officer | no data | データなし | データなし | |
| Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board | 2yrs | データなし | データなし | |
| Chief Medical Officer | 1.4yrs | データなし | データなし |
2.0yrs
平均在職期間
57yo
平均年齢
経験豊富な経営陣: XGNの経営陣は 経験豊富 であると考えられます ( 2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman of the Board of Directors | 5.3yrs | US$132.81k | 0% $ 0 | |
| CEO, President & Director | 2yrs | US$931.95k | 1.17% $ 602.9k | |
| Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board | 4.8yrs | データなし | データなし | |
| Member of Breast Cancer Advisory Board | no data | データなし | データなし | |
| Member of Breast Cancer Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.3yrs | US$33.75k | データなし | |
| Member of Breast Cancer Advisory Board | no data | データなし | データなし | |
| Member of Breast Cancer Advisory Board | no data | データなし | データなし | |
| Member of Breast Cancer Advisory Board | no data | データなし | データなし | |
| Member of Breast Cancer Advisory Board | no data | データなし | データなし | |
| Chairman of Scientific Advisory Board | 4.8yrs | US$130.00k | データなし | |
| Independent Director | 3.3yrs | US$82.70k | 0% $ 0 |
4.8yrs
平均在職期間
63.5yo
平均年齢
経験豊富なボード: XGNの 取締役会 は 経験豊富 であると考えられます ( 4.5年の平均在任期間)。